SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-23-022216
Filing Date
2023-08-07
Accepted
2023-08-07 08:35:08
Documents
15
Period of Report
2023-08-07
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K vtgn20230806_8k.htm   iXBRL 8-K 23759
2 EXHIBIT 99.1 ex_555464.htm EX-99.1 26463
7 logo.jpg GRAPHIC 3124
  Complete submission text file 0001437749-23-022216.txt   194486

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vtgn-20230807.xsd EX-101.SCH 3408
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vtgn-20230807_def.xml EX-101.DEF 11423
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE vtgn-20230807_lab.xml EX-101.LAB 15309
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vtgn-20230807_pre.xml EX-101.PRE 11583
9 EXTRACTED XBRL INSTANCE DOCUMENT vtgn20230806_8k_htm.xml XML 2563
Mailing Address 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 650-577-3600
Vistagen Therapeutics, Inc. (Filer) CIK: 0001411685 (see all company filings)

IRS No.: 205093315 | State of Incorp.: NV | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-37761 | Film No.: 231145769
SIC: 2834 Pharmaceutical Preparations